Nasdaq
$112.37▲ 1.54%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $9.24BShares out 82.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 10.1After-hours26.10.02 06:204Ownership#●●●#●●●
Kymera Therapeutics, Inc.
Insider Nello Mainolfi of Kymera Therapeutics reported a change in beneficial ownership of company securities on October 1, 2026. This filing serves as an official notification of the insider's equity transaction to the SEC.…more
$112.37+1.54%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1After-hours26.10.02 05:10144Ownership
Kymera Therapeutics, Inc.
Nello Mainolfi, an insider at Kymera Therapeutics, has filed SEC Form 144 to report a proposed sale of company shares. This is a standard disclosure regarding an insider's plan to dispose of their holdings.…more
$112.37+1.54%vs prev closeView filingShare - 9.8Regular26.09.08 22:42SCHEDULE 13G/AOwnership
Kymera Therapeutics, Inc.
T. Rowe Price Associates, Inc. has filed a Schedule 13G/A regarding its beneficial ownership in Kymera Therapeutics, Inc. This filing serves as an update to the institutional investor's stake in the company.…more
$112.37+1.54%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoAfter-hours26.10.23 05:01#●●●#●●●
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026…more
Kymera Therapeutics announced that it will report its financial results for the third quarter of 2026 on October 29, 2026. The company will host a conference call and webcast to discuss the results and provide updates.…more
$112.37+1.54%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.2After-hours26.09.03 05:01
●●●●●●●● ●●●●● ●●●●●●
Kymera Therapeutics announced its participation in several upcoming investor conferences throughout September. The company will engage in fireside chats and presentations to discuss its clinical-stage pipeline and business updates.…more
$112.37+1.54%vs prev close - 9.1Pre-market26.09.01 20:04
●●●●●●●● ●●●●● ●●●●●●
Kymera Therapeutics has completed patient enrollment for its Phase 2b trial of KT-621 in atopic dermatitis, with topline data expected by the end of 2026. The company plans to initiate Phase 3 trials by mid-2027, marking a key milestone in its clinical development pipeline.…more
$112.37+1.54%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report